Decline is not inevitable.
A daily, evidence-graded view of everything moving in kidney research : the drugs that slow decline, the science of regeneration, and the mind-body work.
Today brought background science on kidney protection, not new results to act on.
Today's sweep was light, and most of it explained how things work rather than showing what happens to patients. The one high grade item with hard outcomes was a summary of past SGLT2 inhibitor trials, which is worth knowing if you and your doctor have discussed those drugs, but it is not new evidence. The blood pressure review points in a helpful direction without giving a size to the benefit. Two transplant studies and a gum disease study rounded out the day, all observational, meaning they spot patterns rather than prove causes.
Type 2 Diabetes: Chronic Clinical Metabolic Effects of SGLT2 Inhibitors.
This review chapter sums up what SGLT2 inhibitor drugs do over the long run in people with type 2 diabetes. It draws on large randomized trials with hard outcomes like kidney failure, heart failure and death. The benefits for the heart and kidneys show up even in people whose blood sugar was not very high to start with, so the drugs are doing more than lowering sugar. It is a summary of past trials, not a new study, and it does not give a single new effect size.
Effectiveness of culturally adapted lifestyle intervention package on blood pressure: A systematic review.
Researchers searched five large medical databases for lifestyle programs built to fit people's own culture, mixing food changes, exercise and behavior support. They then judged how well those programs lowered blood pressure in different groups of people. Lower blood pressure is one of the strongest ways to protect kidneys over years. This is a review of other studies, and the text available here gives no pooled numbers, so how big the drop is stays unknown.
Clinical Physiology of SGLT2 Inhibitors in Non-diabetic and Diabetic Individuals.
This review explains how SGLT2 inhibitor drugs work inside the body, in people with diabetes and people without it. The drug acts on one small part of the kidney, the proximal tubule, where it blocks the reabsorption of sugar and salt so both leave in the urine. From there the effects spread to blood pressure, fluid balance and how the body uses fuel. The human studies behind it are small physiology studies, so they trace a chain of effects rather than prove that chain causes better outcomes.
Prevalence and Factors Associated with Depression and Anxiety in Patients with Chronic Kidney Disease.
Researchers checked 107 people on dialysis for depression and anxiety, 67 on hemodialysis and 40 on peritoneal dialysis, using a standard questionnaire. They then looked at which personal details, clinical facts and lab values went along with higher scores. Depression and anxiety are common in kidney disease and are tied to worse health and higher death rates. This is an observational study, so it shows links only, not proof that any one factor causes the mood symptoms, and the final rates were not in the text available here.
Prevalence and Systemic Factors Associated with Periodontitis among Kidney Transplant Recipients: A Cross-sectional Study in Vietnam.
Researchers in Vietnam checked how common gum disease (periodontitis) is in people living with a kidney transplant, and what goes along with it. Transplant patients take drugs that hold the immune system down, which can make gum infection easier to get and harder to clear. This was a one time snapshot of a group, so it shows links, not proof that one thing causes the other. The team also looked at blood signs of inflammation, such as C-reactive protein.
Delayed Graft Function After Simultaneous Heart-Kidney Transplantation Across Heart Allocation Eras: Predictors and Impact on Kidney Graft Survival in a National Cohort.
This national study looked at people who received a heart and a kidney in the same operation. It asked what makes the new kidney slow to start working, called delayed graft function, and whether that shortens how long the kidney lasts. It also compared results before and after the rules for handing out donor hearts changed. It is observational, so it shows links, not cause, and the abstract with the numbers was not available here.
Impact of a Residential Yoga and Naturopathy-based Lifestyle Modification on Cardio-Metabolic Risk Factors in Patients with Hypertension: A Retrospective Study.
Researchers looked back at records of people with high blood pressure who stayed at a live-in center doing yoga and naturopathy, and compared heart and metabolic numbers before and after. Looking back at charts with no comparison group shows a link, not proof of cause: the people who choose a residential program differ from those who do not. The abstract gives no number of patients, no length of stay, and no size of effect. It also measured blood pressure and metabolic risk, not kidney filtering rate (eGFR) or protein in the urine, so it says nothing directly about kidneys.
¹⁷⁷Lu-PSMA Radioligand Therapy in Metastatic Castration-resistant Prostate Cancer With Complex Renal Conditions: A Case Series.
Doctors treated men with advanced prostate cancer using a radioactive drug, Lu-177 PSMA, that the kidneys clear from the body. These men also had kidney problems, so they are usually left out of trials and there is little safety information for them. This report describes what happened to the small group the team treated, including how their kidneys held up. It is a case series with no comparison group and no reported patient count in the abstract, so it shows a link at best, not proof of cause.
Paediatric proteomic signatures of cardiometabolic disease-associated traits predict adult disease outcomes.
Researchers measured blood proteins in 273 Hispanic and Latino children and teens, average age about 13, and matched them to 25 early signs of trouble in the liver, body fat, blood vessels and blood sugar. Those signs belong to a cluster doctors call cardiovascular-kidney-metabolic disease, which can later include kidney damage. The study shows a link between childhood protein patterns and adult disease risk, not proof that the proteins cause it. It did not measure kidney filtering rate (eGFR) or protein in the urine, so the kidney part of that link is still indirect.
Shenqi Yanshen Decoction protects against renal and bone injury in chronic kidney disease-mineral and bone disorder with potential involvement of Wnt5a/RhoA/Pkn3 signaling.
A traditional Chinese herbal mix called Shenqi Yanshen Decoction was tested against the kidney and bone damage that often comes with chronic kidney disease. The work was done in lab animals and cells, not in people. The researchers report less kidney and bone injury, and point to one cell signaling route (Wnt5a/RhoA/Pkn3) as a possible reason. This is early animal work, so it does not show the formula helps patients.
Targeting ITIH3 inhibits oxidative stress and autophagy in renal tubular epithelial cells by regulating the HSP90B1/STAT3 axis, thereby alleviating diabetic nephropathy injury.
ITIH3 is a blood protein that runs high in people with kidney damage from diabetes. Researchers blocked it in diabetic mice and in kidney tubule cells grown in the lab. Blocking it lowered cell stress and cut back excess cell self-digestion (autophagy), and kidney injury eased. This was in animals and cells, not people yet, and the blood samples only show the protein is linked to the disease.
SGLT2 Inhibitors as Potential Agents for Prevention, Treatment, and/or Improved Recovery from Acute Kidney Injury.
This review asks whether SGLT2 inhibitors, drugs that make the kidneys pass sugar out in urine, could prevent or speed recovery from sudden kidney failure (acute kidney injury). Sudden kidney failure matters because it can turn into long-term kidney disease or cause death. Most of the evidence it gathers comes from rat and mouse studies, not from patients. So this is a promising idea that has not been proven in people.
SGK2 Promotes NEDD4L-Mediated ACSL4 Ubiquitination to Inhibit Ferroptosis and Alleviate Diabetic Kidney Disease.
Even with today's best diabetes drugs, kidney tubules keep getting damaged, and one cause is a form of cell death driven by iron (ferroptosis). This study found that an enzyme called SGK2 tags a key ferroptosis protein for disposal, which shuts that cell death down and eases kidney damage from diabetes. The work was done in animals and cells, not in people. It points at a possible drug target, nothing more for now.
A Multimodal Lifestyle and Mind-Body Intervention in Rural Primary Care: Implications for Metaflammation in an Appalachian Population.
This describes a program in rural Appalachian primary care that pairs lifestyle changes with mind-body practice. The target is long-running low-level inflammation, sometimes called metaflammation, which tends to show up alongside obesity, high blood pressure, type 2 diabetes and mood disorders. The text available lays out the reasoning and the setting, not measured outcomes. There are no results yet, so nothing here says whether the program works.